Champions Oncology, Inc. (CSBR) Analyst Forecast
Revenue and earnings estimates published by analysts covering Champions Oncology, Inc. (CSBR), and the range of their price targets. Everything on this page is a forecast made by other people — DeltaScreener does not produce estimates or targets of its own.
For Champions Oncology, Inc., analysts forecast revenue rising from $53.64T in 2023 to $70.81T in 2028; the average estimate for 2028 earnings per share is $0.00; 1 analyst contribute to these figures. These are forecasts published by analysts, not results.
Analyst price targets
A price target is one analyst's forecast of where a share might trade, usually over twelve months. Targets are frequently revised, they disagree with each other, and they are not a measure of what a company is worth.
Revenue forecast (USD millions)
The spread between low and high is how far analysts disagree, which is usually a better guide than the average alone.
Earnings per share forecast
Champions Oncology, Inc. (CSBR) forecast — frequently asked questions
What is the analyst price target for Champions Oncology, Inc.?
Analysts covering Champions Oncology, Inc. (CSBR) have a consensus price target of $12.00, 154.2% above the current price of $4.72. Published targets range from $12.00 to $12.00. A price target is a forecast, not a measure of value, and targets are revised often.
What are analysts forecasting for Champions Oncology, Inc.'s earnings?
The average analyst estimate for Champions Oncology, Inc. (CSBR) earnings per share in 2028 is 0.00, with individual estimates between 0.00 and 0.00.
How much revenue is Champions Oncology, Inc. expected to make?
Analysts forecast Champions Oncology, Inc. (CSBR) revenue of $70.81T in 2028, based on 1 published estimates.
How many analysts cover CSBR?
1 analyst contribute estimates for Champions Oncology, Inc. (CSBR). Thin coverage makes an average less reliable.
Popular Stocks
Related stock screens
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.